Bronchial asthma as neurogenic paroxysmal disease - high effectiveness of carbamazepine in asthma monotherapy Source: Eur Respir J 2004; 24: Suppl. 48, 221s Year: 2004
Bronchial asthma as neurogenic inflammatory and paroxysmal disease – efficacy of antiepileptic drug diphenine in asthma therapy Source: Eur Respir J 2006; 28: Suppl. 50, 316s Year: 2006
Efficacy of antiepileptic drugs diphenine and carbamazepine in pharmacotherapy of children with bronchial asthma: is asthma a neurogenic inflammatory disease? Source: Eur Respir J 2006; 28: Suppl. 50, 204s Year: 2006
Efficacy of monotherapy with anticonvulsive drugs topiramate and carbamazepine in bronchial asthma: is asthma a neurological disease? Source: Eur Respir J 2004; 24: Suppl. 48, 130s Year: 2004
Withdrawal of inhaled corticosteroids in people with chronic obstructive pulmonary disease (COPD) in primary care – a randomised controlled trial Source: Annual Congress 2005 - Effects of anti-inflammatory drugs on COPD Year: 2005
Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial Source: Eur Respir J 2007; 30: 457-466 Year: 2007
Severe asthma exacerbations with eosinophilic bronchitis: a randomized controlled comparison of the anti-inflammatory effects of deflazacort vs. prednisone Source: Eur Respir J 2006; 28: Suppl. 50, 441s Year: 2006
The efficacy of omalizumab in severe in asthma after treatment withdrawal Source: Annual Congress 2009 - Towards improving asthma control Year: 2009
Dupilumab efficacy in children with uncontrolled, moderate-to-severe asthma with and without an allergic phenotype Source: Virtual Congress 2021 – Advances in childhood asthma: biologics, biomarkers and infections Year: 2021
Immunological effectiveness of atorvastatin in complex therapy of severe persistent bronchial asthma Source: Annual Congress 2009 - Persistent asthma: still an uncontrolled disease requiring new treatments strategies in 2009 Year: 2009
Effects of combined therapy with nebulized b2 -agonist and anticholinergic in severe exacerbation of chronic obstructive pulmonary disease. Randomized controlled trial Source: Eur Respir J 2007; 30: Suppl. 51, 611s Year: 2007
High or standard initial dose of budesonide to control mild-to-moderate asthma? Source: Eur Respir J 2001; 17: 856-862 Year: 2001
Variability in airway inflammation, symptoms, lung function and reliever use in asthma: anti-inflammatory reliever hypothesis and STIFLE study design Source: ERJ Open Res, 6 (2) 00333-2019; 10.1183/23120541.00333-2019 Year: 2020
Physicians judge add-on omalizumab therapy as an effective treatment for patients with severe persistent allergic asthma: a pooled analysis Source: Eur Respir J 2005; 26: Suppl. 49, 49s Year: 2005
Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003
Anti-IgE: lessons from clinical trials in patients with severe allergic asthma symptomatic despite optimised therapy Source: Eur Respir Rev 2007; 16: 73-77 Year: 2007
Corticosteroid sensitivity in patients with chronic obstructive pulmonary disease is restored by theophylline Source: Annual Congress 2005 - Therapeutic options for COPD: present and future Year: 2005
Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014
Where current pharmacological therapies fall short in COPD: symptom control is not enough Source: Eur Respir Rev 2007; 16: 98-104 Year: 2007